Skip to main content
SpringerLink
Log in

Chemotherapy for Brain Tumors

  • Chapter
  • First Online:
Principles of Neuro-Oncology

Abstract

Gliomas are the most common type of primary malignant brain tumors in adults. They account for 80% of cases. These tumors have been classified by the World Health Organization (WHO), within a four-degree system. Glioblastoma (GB) is the most frequent type of glioma and is associated with a poor prognosis (WHO grade IV). The treatment for these malignancies requires a multimodal work team, which includes chemotherapy and radiotherapy.

However, despite the available treatments, life expectancy is short. Recently, with the innovation of imaging studies, better molecular characterization of these malignancies, in addition to new treatments such as immunotherapy, their prognosis will be better. This review will focus primarily on glial tumors and primary CNS lymphoma, their diagnostic approach and current treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sinning M. Clasificación de los tumores cerebrales. Revista Médica Clínica Las Condes. 2017;28:339–42.

    Article  Google Scholar 

  2. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet. 2012;379(9830):1984–96.

    Article  PubMed  Google Scholar 

  3. Chamberlain MC, Chowdhary SA, Glantz MJ. Anaplastic astrocytomas: biology and treatment. Expert Rev Neurother. 2008;8(4):575–86.

    Article  CAS  PubMed  Google Scholar 

  4. Chowdhary S, Chamberlain MC. Oligodendroglial tumors. Expert Rev Neurother. 2006;6(4):519–32.

    Article  CAS  PubMed  Google Scholar 

  5. Noorbakhsh A, Tang JA, Marcus LP, et al. Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis. J Neurosurg. 2014 Jan;120(1):31–9.

    Article  PubMed  Google Scholar 

  6. Hart MG, et al. Biopsy versus resection for high grade glioma. Cochrane Database Syst Rev. 2011.

    Google Scholar 

  7. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753–64.

    Article  PubMed  Google Scholar 

  8. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.

    Article  CAS  PubMed  Google Scholar 

  9. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009 Oct;15(19):6002–7.

    Article  CAS  PubMed  Google Scholar 

  10. Sarkaria JN, Hu LS, Parney IF, Pafundi DH. Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncology. 2017;20(2):184–91.

    Article  PubMed Central  Google Scholar 

  11. Zhao H, Wang S, Song C, et al. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis. World J Surg Oncol. 2016;14(1):261.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol. 2009;27(8):1275.

    Article  CAS  PubMed  Google Scholar 

  13. Stupp R, Mason WP, van den Bent MJ, et al. European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.

    Article  CAS  PubMed  Google Scholar 

  14. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.

    Article  CAS  PubMed  Google Scholar 

  15. Gramatzki D, Kickingereder P, Hentschel B, et al. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology. 2017;88(15):1422–30.

    Article  CAS  PubMed  Google Scholar 

  16. Blumenthal DT, Gorlia T, Gilbert MR, et al. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol. 2017;19(8):1119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709.

    Article  CAS  PubMed  Google Scholar 

  18. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Herrlinger U, Tzaridis T, Mack F, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019;393(10172):678.

    Article  CAS  PubMed  Google Scholar 

  20. Herrlinger U, Schäfer N, Steinbach JP, et al. Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. J Clin Oncol. 2016;34(14):1611–9.

    Article  CAS  PubMed  Google Scholar 

  21. Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May;64(9):3288–95.

    Article  CAS  PubMed  Google Scholar 

  22. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015 Dec;314(23):2535–43.

    Article  CAS  PubMed  Google Scholar 

  23. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bernard-Arnoux F, Lamure M, Ducray F, et al. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2016 Aug;18(8):1129–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277.

    Article  CAS  PubMed  Google Scholar 

  26. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963.

    Article  PubMed  Google Scholar 

  27. Weller M, van den Bent MJ, Tonn JC, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315–29.

    Article  PubMed  Google Scholar 

  28. Ringel F, Pape H, Sabel M, et al. Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol. 2016 Jan;18(1):96–104.

    Article  PubMed  Google Scholar 

  29. van Linde ME, Brahm CG, de Witt Hamer PC, et al. Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. J Neurooncol. 2017;135(1):183.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733.

    Article  CAS  PubMed  Google Scholar 

  31. Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954.

    Article  CAS  PubMed  Google Scholar 

  32. Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010;28(30):4601.

    Article  CAS  PubMed  Google Scholar 

  33. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192–202.

    Article  PubMed  Google Scholar 

  34. Hirst TC, et al. Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? Br J Cancer. 2013;108(1):64–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Kim JT, et al. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep. 2006;16(1):33–9.

    PubMed  Google Scholar 

  36. Brandes AA, et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol. 2004;22(9):1598–604.

    Article  CAS  PubMed  Google Scholar 

  37. Franceschi E, et al. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br J Cancer. 2004;91(6):1038–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Reardon DA, et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 2005;103(2):329–38.

    Article  CAS  PubMed  Google Scholar 

  39. Brandes AA, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004;22(23):4779–86.

    Article  CAS  PubMed  Google Scholar 

  40. Almenawer SA, Badhiwala JH, Alhazzani W, et al. Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro Oncol. 2015;17(6):868.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027.

    Article  CAS  PubMed  Google Scholar 

  42. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527–35.

    Article  CAS  PubMed  Google Scholar 

  43. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707.

    Article  CAS  PubMed  Google Scholar 

  44. Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916.

    Article  PubMed  Google Scholar 

  45. Celis M, et al. Primer consenso mexicano sobre recomendaciones de la atención multidisciplinaria del paciente con glioblastoma multiforme (GBM). Grupo Interdisciplinar Mexicano de Investigación en Neurooncología (GIMINO). Gac Med Mex. 2015;151:403–15.

    PubMed  Google Scholar 

  46. Nuño M, et al. Survival and prognostic factors of anaplastic gliomas. Neurosurgery. 2013;73:458–65.

    Article  PubMed  Google Scholar 

  47. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995;345(8956):1008.

    Article  CAS  PubMed  Google Scholar 

  48. Perry JR, Bélanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28(12):2051.

    Article  CAS  PubMed  Google Scholar 

  49. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707–14.

    Article  CAS  PubMed  Google Scholar 

  50. Cairncross G, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013 Jan 20;31(3):337–43.

    Article  CAS  PubMed  Google Scholar 

  51. van den Bent M, Brandes AA, Taphoorn MJ. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2013;31:344–50.

    Article  PubMed  Google Scholar 

  52. Brodie M, et al. Enzyme induction with antiepileptic drugs. Epilepsia. 2013;54(1):11–27.

    Article  CAS  PubMed  Google Scholar 

  53. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol. 2005;72:255–60.

    Article  CAS  PubMed  Google Scholar 

  54. van den Bent MJ, Baumert B, Erridge SC, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390:1645–53.

    Article  PubMed  PubMed Central  Google Scholar 

  55. van den Bent MJ, Erridge S, Vogelbaum MA, et al. Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. J Clin Oncol. 2019;37(Suppl):abstr 2000.

    Article  Google Scholar 

  56. Olar A, et al. Biomarkers classification and therapeutic decision-making for malignant gliomas. Curr Treatment Options Oncol. 2012;13:417–36.

    Article  Google Scholar 

  57. Tabatabai G, et al. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol. 2010 Nov;120(5):585–92.

    Article  CAS  PubMed  Google Scholar 

  58. Senetta R, et al. A “weighted” fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors. J Neuropathol Exp Neurol. 72(5):432–41.

    Google Scholar 

  59. Fontaine D, et al. Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice. Rev Neurol (Paris). 164(6–7):595–604.

    Google Scholar 

  60. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. van den Bent M, et al. IDH1 and IDH2 mutations are prognostic but not predictive for out-come in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16(5):1597–604.

    Article  PubMed  Google Scholar 

  62. Hartmann C, et al. Patients with IDH1wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, andIDH1 mutation status accounts for the unfavor-able prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707–18.

    Article  PubMed  Google Scholar 

  63. Metellus P, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 2010;120(6):719–29. Epub 2010/11/17.

    Article  PubMed  Google Scholar 

  64. Hartmann C, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469–74.

    Article  PubMed  Google Scholar 

  65. Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol. 2009;68(12):1319–25.

    Article  CAS  PubMed  Google Scholar 

  66. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6):597–602.

    Article  CAS  PubMed  Google Scholar 

  67. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985.

    Article  PubMed  Google Scholar 

  68. Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentonal adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012;30:3065–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Ryken TC, Parney I, Buatti J, et al. The role of radiotherapy in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015;125(3):551.

    Article  CAS  PubMed  Google Scholar 

  70. Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2002;52:316–24.

    Article  PubMed  Google Scholar 

  71. Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1998;34:1902–9.

    Article  CAS  PubMed  Google Scholar 

  72. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20:2267–76.

    Article  CAS  PubMed  Google Scholar 

  73. Fisher BJ, Hu C, Macdonald DR, Lesser GJ, et al. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys. 2015;91(3):497.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Grossman SA, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17(16):5473–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Neyns B, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010;116(12):2868–77.

    Article  CAS  PubMed  Google Scholar 

  76. Reardon D, Omuro A, Brandes A, et al. Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro Oncol. 2017;19(Suppl 36):iii21.

    Article  PubMed Central  Google Scholar 

  77. Mildenberger I. The promises of immunotherapy in gliomas. Curr Opin Neurol. 2017;30(6):650–8.

    Article  CAS  PubMed  Google Scholar 

  78. Cocco E, Scaltriti M, Drilon A, et al. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014 May;46(5):444–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Brandsma D, Bromberg JEC. Primary CNS lymphoma in HIV infection. Handb Clin Neurol. 2018;152:177–86.

    Article  PubMed  Google Scholar 

  82. Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (alliance 50202). J Clin Oncol. 2013;31(25):3061–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003 Jan 15;21(2):266–72.

    Article  PubMed  Google Scholar 

  84. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24(36):5711–5.

    Article  PubMed  Google Scholar 

  85. Cady FM, O’Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, Porter AB, Kurtin PJ, Johnston PB, Dogan A, Remstein ED. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol. 2008 Oct 10;26(29):4814–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Li CH, Yang CF, Yang HC, et al. Risk prediction for early mortality in patients with newly diagnosed primary CNS lymphoma. J Cancer. 2019;10(17):3958–66.

    Article  Google Scholar 

  87. Batchelor T, Carson K, O’Neill A, Grossman SA, Alavi J, New P, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21(6):1044–9.

    Article  CAS  PubMed  Google Scholar 

  88. Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–20.

    Article  CAS  PubMed  Google Scholar 

  89. Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217–27.

    Article  PubMed  Google Scholar 

  90. Bromberg JEC, Issa S, Bakunina K, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019;20(2):216.

    Article  CAS  PubMed  Google Scholar 

  91. Schaff LR, Grommes C. Updates on primary central nervous system lymphoma. Curr Oncol Rep. 2018 Feb 28;20(2):11.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62(10):1595–600.

    Article  PubMed  Google Scholar 

  93. Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036–47.

    Article  CAS  PubMed  Google Scholar 

  94. Sandor V, Stark-Vancs V, Pearson D, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol. 1998;16(9):3000–6.

    Article  CAS  PubMed  Google Scholar 

  95. Pels H, Juergens A, Glasmacher A, Schulz H, Engert A, Linnebank M, et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neuro-Oncol. 2009;91(3):299–305.

    Article  CAS  Google Scholar 

  96. Grimm SA, McCannel CA, Omuro AM, Ferreri AJ, Blay JY, Neuwelt EA, et al. Primary CNS lymphoma with intraocular involvement: international PCNSL collaborative group report. Neurology. 2008;71(17):1355–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24(24):3865–70.

    Article  CAS  PubMed  Google Scholar 

  98. Illerhaus G, Muller F, Feuerhake F, et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93(1):147–8.

    Article  CAS  PubMed  Google Scholar 

  99. Freilich RJ, Delattre JY, Monjour A, et al. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology. 1996;46(2):435–9.

    Article  CAS  PubMed  Google Scholar 

  100. Ney DE, Reiner AS, Panageas KS, et al. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer. 2010;116(19):4605–12.

    Article  PubMed  Google Scholar 

  101. Abrey LE, et al. Report of an International Workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(2):5034–43.

    Article  PubMed  Google Scholar 

  102. Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neuro-Oncol. 2006;80(2):159–65.

    Article  Google Scholar 

  103. Pentsova E, Deangelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neuro-Oncol. 2014;117(1):161–5.

    Article  CAS  Google Scholar 

  104. Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008;26(15):2512–8.

    Article  PubMed  Google Scholar 

  105. Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology. 2007;69(11):1178–82.

    Article  PubMed  Google Scholar 

  106. Nayak L, Iwamoto FM, LaCasce A, Mukundan S, MGM R, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Instituto Nacional de Cancerología-México, Mexico City, Mexico

    Jorge Luis Martínez-Tlahuel, Jorge Adan Alegría-Baños & Angelica Exayana Alderete-López

  2. Department of Medical Oncology, Médica Sur, Mexico City, Mexico

    Pamela Denisse Soberanis-Piña

  3. Department of Hematology, Hospital Pediátrico Santa María, Chihuahua, Mexico

    Luis Alonso Acosta-Ayala

  4. Inmunoterapy Lab, Universidad Nacional Autónoma de México, Mexico City, Mexico

    Montserrat Aline Rosas-Alvarado

  5. Department of Pediatry, Hospital Ángeles Lindavista, Mexico City, Mexico

    Yoli Lizbeth Suárez-Bobadilla

Authors
  1. Jorge Luis Martínez-Tlahuel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge Adan Alegría-Baños
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pamela Denisse Soberanis-Piña
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luis Alonso Acosta-Ayala
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Montserrat Aline Rosas-Alvarado
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoli Lizbeth Suárez-Bobadilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Angelica Exayana Alderete-López
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Neurosurgery, Aurora Neuroscience Innovation Institute, Milwaukee, WI, USA

    Alejandro Monroy-Sosa

  2. Department of Neurosurgery, Aurora Neuroscience Innovation Institute, Milwaukee, WI, USA

    Srikant S. Chakravarthi

  3. Instituto Nacional de Cancerología, Mexico City, Mexico

    Jaime G. de la Garza-Salazar

  4. Instituto Nacional de Cancerología, Mexico City, Mexico

    Abelardo Meneses Garcia

  5. Neeka Health, LLC, Milwaukee, WI, USA

    Amin B. Kassam

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Martínez-Tlahuel, J.L. et al. (2021). Chemotherapy for Brain Tumors. In: Monroy-Sosa, A., Chakravarthi, S.S., de la Garza-Salazar, J.G., Meneses Garcia, A., Kassam, A.B. (eds) Principles of Neuro-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-54879-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54879-7_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54878-0

  • Online ISBN: 978-3-030-54879-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation